Systemic Lupus Clinical Trial
Official title:
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)
Primary objectives :
- To investigate the safety and the tolerability of ATO by IV infusions to patients with
SLE,
- To determine the maximum tolerated dose of ATO.
Secondary objectives :
- Evaluation of the clinical and biological response of the SLE to ATO,
- Time of relapse in case of positive response,
- Determination of the efficacy,
- Pharmacokinetic study of ATO.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03749044 -
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
|
N/A | |
| Completed |
NCT03218033 -
Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus
|
N/A | |
| Not yet recruiting |
NCT03752983 -
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|
||
| Recruiting |
NCT03819777 -
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
|
||
| Recruiting |
NCT04894253 -
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
|
||
| Not yet recruiting |
NCT03164720 -
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
|
||
| Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Completed |
NCT04108611 -
Immune Adsorption Role in Treatment of Resistant Lupus
|
N/A | |
| Not yet recruiting |
NCT04256577 -
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
|
||
| Completed |
NCT03540823 -
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
|
Phase 4 |